November 26, 2025 — Leads & Copy — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) announced today that CTV News’ W5 will air a three-part series about the company’s allegations of stock market manipulation.
The series, which begins today, features top CTV News journalist Jon Woodward investigating Quantum Biopharma’s allegations of stock market manipulation. Woodward’s article, “Was a Canadian company’s multiple sclerosis research nearly derailed by ‘market manipulation’?” describes Part One of the series. The series delves into “stock spoofing,” an illegal market manipulation tactic in both Canada and the United States, and forms the basis of Quantum Biopharma’s USD $700 million lawsuit against CIBC and RBC.
The first part of the W5 investigative series can be viewed today on CTV News at: W5: MS research derailed by stock market spoofing: lawsuit
Quantum BioPharma CEO Zeeshan Saeed expressed gratitude to W5 for their investigation into stock spoofing, highlighting its harmful effects on retail investors. Saeed stated the company’s goal is to advance Lucid-MS, a drug with the potential to reverse nerve cell degradation, a key feature of multiple sclerosis. He added the drug has demonstrated potential in animal studies. Saeed hopes that by highlighting their experience, other companies and shareholders can avoid similar situations.
Quantum BioPharma Ltd. is a biopharmaceutical company focused on innovative assets and biotech solutions for neurodegenerative and metabolic disorders and alcohol misuse disorders. Its lead compound, Lucid-MS, is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
Quantum BioPharma also invented unbuzzd™, an OTC version spun out to Unbuzzd Wellness Inc., where Quantum BioPharma retains 19.86% ownership as of September 30, 2025. The agreement includes royalty payments of 7% of sales from unbuzzd™ until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains all rights to develop similar products for pharmaceutical and medical uses.
The company, through its subsidiary FSD Strategic Investments Inc., also maintains a portfolio of strategic investments representing loans secured by residential or commercial property.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board; Email: Zsaeed@quantumbiopharma.com; Telephone: (833) 571-1811
Source: Quantum BioPharma Ltd.
